Literature DB >> 15578688

Microsatellite distribution and indication for locoregional therapy in small hepatocellular carcinoma.

Atsushi Sasaki1, Seiichiro Kai, Yukio Iwashita, Seitaro Hirano, Masayuki Ohta, Seigo Kitano.   

Abstract

BACKGROUND: Intrahepatic disease recurrence is observed frequently after locoregional therapies for patients with hepatocellular carcinoma (HCC). However, the indication for locoregional therapy is still unclear. To clarify the indication for locoregional therapy for small HCC tumors, the authors measured the distance of microsatellites from the main tumor and analyzed the relation between this distance and clinicopathologic factors.
METHODS: The authors retrospectively analyzed 100 patients with small HCC tumors (</= 5 cm in dimension) treated by curative hepatectomy. A microsatellite was defined as invasion into the portal vein or intrahepatic metastasis, and the distance from the main tumor to the most distant microsatellite was determined under light microscopy. The current study investigated the relation between microsatellite distance (0 mm if none present, </= 5 mm, and > 5 mm) and clinicopathologic factors, as well as overall and disease-free survival rates after hepatectomy.
RESULTS: Of the 100 patients, 46 had microsatellites with a mean distance of 9.9 mm (median, 5.0 mm). Of the clinicopathologic factors investigated, tumor grade and preoperative alpha-fetoprotein level significantly correlated with the presence of a microsatellite. Tumor size and distance to the microsatellite were significantly correlated. All but 1 tumor associated with a microsatellite distance > 5 mm was a high-grade tumor > 25 mm in greatest dimension. The overall survival rate of patients with a microsatellite distance of > 5 mm was lower than that of patients with a microsatellite distance < 5 mm.
CONCLUSIONS: Locoregional therapy, including limited resection and ablation therapies, was appropriate for patients with low-grade HCC tumors or with tumors < 25 mm in diameter. (c) 2004 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15578688     DOI: 10.1002/cncr.20798

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  45 in total

1.  Drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma: does size really matter?

Authors:  Sieh-Yang Lee; Hsin-You Ou; Chun-Yen Yu; Tung-Liang Huang; Leo Leung-Chit Tsang; Yu-Fan Cheng
Journal:  Diagn Interv Radiol       Date:  2020-05       Impact factor: 2.630

Review 2.  Are Tumor Exposure and Anatomical Resection Antithetical during Surgery for Hepatocellular Carcinoma? A Critical Review.

Authors:  Guido Torzilli; Matteo Donadon; Matteo Cimino
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

3.  Predicting the grade of hepatocellular carcinoma based on non-contrast-enhanced MRI radiomics signature.

Authors:  Minghui Wu; Hongna Tan; Fei Gao; Jinjin Hai; Peigang Ning; Jian Chen; Shaocheng Zhu; Meiyun Wang; Shewei Dou; Dapeng Shi
Journal:  Eur Radiol       Date:  2018-11-07       Impact factor: 5.315

Review 4.  Therapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI.

Authors:  Yasunori Minami; Naoshi Nishida; Masatoshi Kudo
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

5.  The role of radiofrequency ablation to liver transection surface in patients with close tumor margin of HCC during hepatectomy-a case matched study.

Authors:  C Nicholas Kotewall; Tan To Cheung; Wong Hoi She; Ka Wing Ma; Simon Hing Ying Tsang; Jeff Wing Chiu Dai; Albert Chi Yan Chan; Kenneth Siu Ho Chok; Chung Mau Lo
Journal:  Transl Gastroenterol Hepatol       Date:  2017-04-28

6.  Pathway of care of hepatocellular carcinoma in 2017.

Authors:  Federica Invernizzi; Massimo Colombo
Journal:  Hepat Oncol       Date:  2017-06-21

7.  ASO Author Reflections: A New Look at the Clinical Significance of MVI in Hepatocellular Carcinoma.

Authors:  Derek J Erstad; Kenneth K Tanabe
Journal:  Ann Surg Oncol       Date:  2019-05-20       Impact factor: 5.344

8.  Radiofrequency ablation versus surgical resection for hepatocellular carcinoma in Childs A cirrhotics-a retrospective study of 1,061 cases.

Authors:  Jiwei Huang; Roberto Hernandez-Alejandro; Kristopher P Croome; Lvnan Yan; Hong Wu; Zheyu Chen; Pankaj Prasoon; Yong Zeng
Journal:  J Gastrointest Surg       Date:  2010-10-30       Impact factor: 3.452

9.  Safety margin of radiofrequency ablation for hepatocellular carcinoma: a prospective study using magnetic resonance imaging with superparamagnetic iron oxide.

Authors:  Kuniaki Fukuda; Kensaku Mori; Naoyuki Hasegawa; Katsuhiro Nasu; Kazunori Ishige; Yoshikazu Okamoto; Masanari Shiigai; Masato Abei; Manabu Minami; Ichinosuke Hyodo
Journal:  Jpn J Radiol       Date:  2019-05-17       Impact factor: 2.374

10.  Radiofrequency ablation combined with chemoembolization for intermediate-sized (3-5 cm) hepatocellular carcinomas under dual guidance of biplane fluoroscopy and ultrasonography.

Authors:  Ji Hye Min; Min Woo Lee; Dong Ik Cha; Yong Hwan Jeon; Sung Wook Shin; Sung Ki Cho; Hyunchul Rhim; Hyo K Lim
Journal:  Korean J Radiol       Date:  2013-02-22       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.